Skip to main content Accessibility help
×
Home

Association between atypical antipsychotic agents and type 2 diabetes: Review of prospective clinical data

  • Chris Bushe (a1) and Brian Leonard (a2)

Abstract

Background

Most evidence suggesting an association between schizophrenia, antipsychotic medications and diabetes has been based on retrospective studies not controlled for important confounders.

Aims

To compare diabetogenic risk between antipsychotic medications; and to describe the limitations of current prospective data-sets.

Method

Systematic review of prospective clinical data.

Results

No difference in the incidence of glycaemic abnormalities between placebo cohorts and antipsychotic medication cohorts was identified. No significant difference between any of the antipsychotic medications studied in terms of their association with glycaemic abnormalities was identified. Treatment-related weight gain did not appear to increase the risk of developing diabetes.

Conclusions

Diabetogenic potential ascribed to atypical antipsychotic drugs, resulting from retrospective studies, may be incorrect. Cohort sizes and incomplete sampling must preclude any definitive conclusions. Long-term, large, comparative prospective trials are needed, along with agreement upon glucose measurement of choice.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Association between atypical antipsychotic agents and type 2 diabetes: Review of prospective clinical data
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Association between atypical antipsychotic agents and type 2 diabetes: Review of prospective clinical data
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Association between atypical antipsychotic agents and type 2 diabetes: Review of prospective clinical data
      Available formats
      ×

Copyright

Corresponding author

Dr Chris Bushe, Eli Lilly & Co. Ltd, Lilly House, Priestley Road, Basingstoke RG24 9NL, UK. Tel: (0) 1256 775971; fax: (0) 1256 775534; e-mail: bushe_chns@lilly.com

Footnotes

Hide All

Declaration of interest

C.B. is employed by Eli Lilly & Co. Ltd. B.L. has been consultant to Eli Lilly & Co. in regard to diabetes and schizophrenia.

Footnotes

References

Hide All
Alberti, K. G. (1996) The clinical implications of impaired glucose tolerance. Diabetic Medicine, 13, 927937.
American Diabetes Association (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 20, 11831197.
Bushe, C. & Holt, R. (2004) Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. British Journal of Psychiatry, 184 (suppl. 47), s67s71.
Buse, J. B., Cavazzoni, P., Hornbuckle, K., et al (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of Clinical Epidemiology, 56, 164170.
Cheta, D., Dumitrescu, C., Georgescu, M., et al (1990) A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes and Metabolism, 16, 1115.
Citrome, L. (2003) Antipsychotic medication treatment and new prescriptions for insulin and oral hypoglycaemics. European Neuropsychopharmacology 13 (suppl. 4), S306.
Cohn, T., Wolever, T., Zipursky, R., et al (2002) Screening for diabetes and impaired glucose tolerance in patients on antipsychotic medication. International Journal of Neuropsychopharmacology, 5 (suppl. 1), S168.
Cunningham, F., Lambert, B., Miller, D. R., et al (2003) Antipsychotic-induced diabetes in Veteran schizophrenic patients. Pharmacoepidemiology and Drug Safety, 12 (suppl. 1), S154S155.
David, S. R., Taylor, C. C., Kinon, B. J., et al (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics, 22, 10851096.
Dynes, J. B. (1969) Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Diseases of the Nervous System, 30, 341344.
Food and Drug Administration (2003) Abilify (Aripiprazole) Tablets. Center for Drug Evaluation and Research, New and Generic Drug Approvals: 1998–2003. http://www.fda.gov/cder/foi/nda/2002/21-436=Abilify.htm
Gourdy, P., Ruidavets, J. B., Ferrieres, J., et al (2001) Prevalence of type 2 diabetes and impaired fasting glucose in the middle-aged population of three French regions – the MONICA study 1995–97. Diabetes and Metabolism, 27, 347358.
Green, M. (2003) Managing schizophrenia in patients with co-morbid diabetes. European Neuropsychopharmacology, 13 (suppl. 4), S306.
Kane, J. M., Carson, W. H., Saha, A. R., et al (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry, 63, 763771.
Kinon, B. J., Gilmore, J. A., Liu, H., et al (2003) Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology, 28 (suppl. 2), 5568.
Kornegay, C. J., Vasilakis-Scaramozza, C. & Jick, H. (2002) Incident diabetes associated with ant psychotic use in the United Kingdom general practice research database. Journal of Clinical Psychiatry, 63, 758762.
Koro, C. E., Fedder, D. O., L'Italien, G. J., et al (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case–control study. BMJ, 325, 243247.
Lamberti, J., Crilly, J., Maharaj, K., et al (2003) Prevalence of adult-onset diabetes among outpatients receiving antipsychotic drugs. Schizophrenia Research, 60 (suppl.), S360.
Lieberman, J. A., Phillips, M., Gu, H., et al (2003) Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology, 28, 9951003.
Lindenmayer, J. P., Czobor, P., Volavka, J., et al (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry, 160, 290296.
Marder, S. R., McQuade, R. D., Stock, E., et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research, 61, 123136.
Meehan, K., Zhang, F., David, S., et al (2001) A double-blind randomised comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology, 21, 389397.
Mukherjee, S., Schnur, D. B. & Reddy, R. (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet, i, 495.
National Institute for Clinical Excellence (2002) Full Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia (Technology Appraisal Guidance no. 43). London: NICE. http://www.nice.org.uk/article.asp?a=32933
Purdon, S. E., Jones, B. D., Stip, E., et al (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olazapine, risperidone or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Archives of General Psychiatry, 57, 249258.
Rein, W. & Arvanitis, L. (2003) Antipsychotic effect of four different compounds – results of the meta-trial. European Neuropsychopharmacology, 13 (suppl. 4). S323.
Ryan, M. C. & Thakore, J. H. (2002) Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sciences, 71, 239257.
Ryan, M. C., Collins, P. & Thakore, J. H. (2003) Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. American Journal of Psychiatry, 160, 284289.
Sernyak, M. J., Leslie, D. L., Alarcon, R. D., et al (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 159, 561566.
Shiloah, E., Witz, S., Abramovitch, Y., et al (2003) Effect of psychotic stress in nondiabetic subjects on beta-cell function and insulin sensitivity. Diabetes Care, 26, 14621467.
Sowell, M., Mukhopadhyay, N., Cavazzoni, P., et al (2003) Risk factors for diabetes during clinical trials of antipsychotics. Journal of Psychopharmacology, 17 (suppl.), A53.
Subramaniam, M., Chong, S. A. & Pek, E. (2003) Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Canadian Journal of Psychiatry, 48, 345347.
Taylor, D. M. & McAskill, R. (2000) Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatrica Scandinavica, 101, 416432.
Taylor, D. M., Young, C., Mahomed, R., et al (2003) A prevalence study of impaired glucose tolerance and diabetes mellitus in hospitalised patients with schizophrenia. European Neuropsychopharmacology, 13 (suppl. 4), S323.
UK Prospective Diabetes Study Group (1995) Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes, 44, 12491258.
UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837853.
Wang, H., Sowell, M. O., Cavazzoni, P., et al (2003) Retrospective assessment of pre-existing diabetes progression in clinical trials of patients with serious mental illness. Schizophrenia Research, 60 (suppl), S369.
World Health Organization (1999) Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part I: Diagnosis and Classification of Diabetes Mellitus. WHO/NCD/NCS/99.2. Geneva: WHO.
Wright, P., Birkett, M., David, S., et al (2001) Doubleblind placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. American Journal of Psychiatry, 158, 11491151.
Yu, B. P., Oritz, T., Chong, Y. S., et al (2002) Atypical antipsychotics in patients with diabetes mellitus: a retrospective review. Drug Benefit Trends, 14, 4245.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Association between atypical antipsychotic agents and type 2 diabetes: Review of prospective clinical data

  • Chris Bushe (a1) and Brian Leonard (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *